[{"indications": "Indications\u00a0see notes above and under Dose", "name": "CABERGOLINE - BROMOCRIPTINE AND OTHER DOPAMINERGIC DRUGS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.1 Bromocriptine and other dopaminergic drugs", "CABERGOLINE"], "cautions": "Cautions\u00a0\n(From 6.7.1 Bromocriptine and other dopaminergic drugs: British National Formulary)\nCautions\u00a0see notes below; also bromocriptine and cabergoline should be used with caution in patients with a history of peptic ulcer, particularly in acromegalic patients. Treatment should be withdrawn if gastro-intestinal bleeding occurs. In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment). Bromocriptine and cabergoline should be used with caution in patients with Raynaud\u2019s syndrome and cardiovascular disease (see also Contra-indications under Bromocriptine, below). Monitor for fibrotic disease (see Fibrotic Reactions, below). Caution is also advised in patients with a history of serious mental disorders (especially psychotic disorders) and in those with acute porpyhria (see section 9.8.2). Tolerance may be reduced by alcohol.; also monthly pregnancy tests during the amenorrhoeic period; advise non-hormonal contraception if pregnancy not\r\ndesired (see also Pregnancy, below); interactions: Appendix 1 (cabergoline)", "side-effects": "Side-effects\u00a0\n(From 6.7.1 Bromocriptine and other dopaminergic drugs: British National Formulary)\nSide-effects\u00a0Nausea, constipation, and headache are common side-effects of bromocriptine and cabergoline. Paraesthesia has been reported rarely. Other reported side-effects include hypotension (see also Hypotensive Reactions, below), drowsiness (see also Driving, below), dyskinesia, pathological gambling, increased libido, hypersexuality, leg cramps, allergic skin reactions, alopecia, and peripheral oedema. Bromocriptine and cabergoline have been associated with pleuritis, pleural effusion, cardiac valvulopathy, pericardial effusion, constrictive pericarditis, and retroperitoneal, pleural, and pulmonary fibrosis (see Fibrotic Reactions). ; also\r\ncardiac valvulopathy, dyspepsia, gastritis, epigastric and abdominal\r\npain, angina, syncope, depression, confusion, hallucinations, breast\r\npain; rarely vomiting, palpitation, epistaxis, digital\r\nvasospasm, hot flushes, transient hemianopia, muscle weakness; also reported erythromelalgia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/21316.htm", "doses": ["Prevention of lactation (but see notes above and under\r\nContra-indications), during first day postpartum, 1\u00a0mg as a single\r\ndose; suppression of established lactation (but see notes above) 250\u00a0micrograms\r\nevery 12\u00a0hours for 2 days; child under\r\n16 years, not recommended", "Hyperprolactinaemic disorders, 500\u00a0micrograms weekly (as a single\r\ndose or as 2 divided doses on separate days) increased\r\nat monthly intervals in steps of 500\u00a0micrograms until optimal therapeutic\r\nresponse (usually 1\u00a0mg weekly, range 0.25\u20132\u00a0mg weekly) with monthly\r\nmonitoring of serum prolactin levels; reduce initial dose and increase\r\nmore gradually if patient intolerant; over 1\u00a0mg weekly give as divided\r\ndoses; up to 4.5\u00a0mg weekly has been used in hyperprolactinaemic patients; child under 16 years, not recommended", "Parkinson\u2019s disease, section 4.9.1"], "pregnancy": "Pregnancy\u00a0exclude pregnancy before starting and discontinue\r\n1 month before intended conception (ovulatory cycles persist for 6\r\nmonths)\u2014discontinue if pregnancy occurs during treatment (specialist\r\nadvice needed)"}, {"indications": "Indications\u00a0see notes above and under Dose", "name": "CABERGOLINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.7 Other endocrine drugs", "6.7.1 Bromocriptine and other dopaminergic drugs", "CABERGOLINE"], "cautions": "Cautions\u00a0\n(From 6.7.1 Bromocriptine and other dopaminergic drugs: British National Formulary)\nCautions\u00a0see notes below; also bromocriptine and cabergoline should be used with caution in patients with a history of peptic ulcer, particularly in acromegalic patients. Treatment should be withdrawn if gastro-intestinal bleeding occurs. In hyperprolactinaemic patients, the source of the hyperprolactinaemia should be established (i.e. exclude pituitary tumour before treatment). Bromocriptine and cabergoline should be used with caution in patients with Raynaud\u2019s syndrome and cardiovascular disease (see also Contra-indications under Bromocriptine, below). Monitor for fibrotic disease (see Fibrotic Reactions, below). Caution is also advised in patients with a history of serious mental disorders (especially psychotic disorders) and in those with acute porpyhria (see section 9.8.2). Tolerance may be reduced by alcohol.; also monthly pregnancy tests during the amenorrhoeic period; advise non-hormonal contraception if pregnancy not\r\ndesired (see also Pregnancy, below); interactions: Appendix 1 (cabergoline)", "side-effects": "Side-effects\u00a0\n(From 6.7.1 Bromocriptine and other dopaminergic drugs: British National Formulary)\nSide-effects\u00a0Nausea, constipation, and headache are common side-effects of bromocriptine and cabergoline. Paraesthesia has been reported rarely. Other reported side-effects include hypotension (see also Hypotensive Reactions, below), drowsiness (see also Driving, below), dyskinesia, pathological gambling, increased libido, hypersexuality, leg cramps, allergic skin reactions, alopecia, and peripheral oedema. Bromocriptine and cabergoline have been associated with pleuritis, pleural effusion, cardiac valvulopathy, pericardial effusion, constrictive pericarditis, and retroperitoneal, pleural, and pulmonary fibrosis (see Fibrotic Reactions). ; also\r\ncardiac valvulopathy, dyspepsia, gastritis, epigastric and abdominal\r\npain, angina, syncope, depression, confusion, hallucinations, breast\r\npain; rarely vomiting, palpitation, epistaxis, digital\r\nvasospasm, hot flushes, transient hemianopia, muscle weakness; also reported erythromelalgia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/21316.htm", "doses": ["Prevention of lactation (but see notes above and under\r\nContra-indications), during first day postpartum, 1\u00a0mg as a single\r\ndose; suppression of established lactation (but see notes above) 250\u00a0micrograms\r\nevery 12\u00a0hours for 2 days; child under\r\n16 years, not recommended", "Hyperprolactinaemic disorders, 500\u00a0micrograms weekly (as a single\r\ndose or as 2 divided doses on separate days) increased\r\nat monthly intervals in steps of 500\u00a0micrograms until optimal therapeutic\r\nresponse (usually 1\u00a0mg weekly, range 0.25\u20132\u00a0mg weekly) with monthly\r\nmonitoring of serum prolactin levels; reduce initial dose and increase\r\nmore gradually if patient intolerant; over 1\u00a0mg weekly give as divided\r\ndoses; up to 4.5\u00a0mg weekly has been used in hyperprolactinaemic patients; child under 16 years, not recommended", "Parkinson\u2019s disease, section 4.9.1"], "pregnancy": "Pregnancy\u00a0exclude pregnancy before starting and discontinue\r\n1 month before intended conception (ovulatory cycles persist for 6\r\nmonths)\u2014discontinue if pregnancy occurs during treatment (specialist\r\nadvice needed)"}, {"indications": "Indications\u00a0alone or as adjunct to co-beneldopa\r\nor co-careldopa in Parkinson\u2019s disease where dopamine-receptor agonists\r\nother than ergot derivative not appropriate; endocrine disorders (section 6.7.1)", "name": "CABERGOLINE - DOPAMINE-RECEPTOR AGONISTS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Dopamine-receptor agonists"], "cautions": "Cautions\u00a0see Cabergoline in section 6.7.1 and notes above", "side-effects": "Side-effects\u00a0\n(From Dopamine-receptor agonists: British National Formulary)\nDopamine-receptor agonists and Cabergoline, %s\n(From CABERGOLINE: British National Formulary)\nSide-effects\u00a0see notes above; also cardiac valvulopathy, dyspepsia, gastritis, epigastric and abdominal pain, angina, syncope, depression, confusion, hallucinations, breast pain; rarely vomiting, palpitation, epistaxis, digital vasospasm, hot flushes, transient hemianopia, muscle weakness; also reported erythromelalgia", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128145.htm", "doses": ["Initially 1\u00a0mg daily, increased by increments of 0.5\u20131\u00a0mg\r\nat 7 or 14 day intervals; max. 3\u00a0mg daily", "Concurrent dose of levodopa may be decreased gradually while dose of cabergoline is increased"], "pregnancy": "Pregnancy\u00a0see Cabergoline, section 6.7.1"}]